Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLA NYSE:IKT NASDAQ:TARA NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.84-1.8%$0.92$0.63▼$1.78$30.74M0.3416,961 shs1,096 shsIKTInhibikase Therapeutics$1.73-3.9%$1.84$1.12▼$4.20$128.61M0.91198,297 shs82,089 shsTARAProtara Therapeutics$3.11-1.3%$3.12$1.60▼$10.48$121.53M1.42202,988 shs140,678 shsTNYATenaya Therapeutics$0.67-3.0%$0.66$0.36▼$4.01$113.12M3.012.41 million shs863,784 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma-1.18%-4.57%-5.30%-25.78%-42.01%IKTInhibikase Therapeutics-3.89%+4.85%-10.36%-17.97%+32.06%TARAProtara Therapeutics-1.27%-2.20%+11.07%-7.72%+50.24%TNYATenaya Therapeutics-2.99%-8.13%+15.65%+53.11%-75.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESLAEstrella Immunopharma2.3617 of 5 stars3.55.00.00.00.61.70.0IKTInhibikase Therapeutics1.6839 of 5 stars3.33.00.00.00.00.01.3TARAProtara Therapeutics1.6983 of 5 stars3.61.00.00.02.30.00.6TNYATenaya Therapeutics3.5269 of 5 stars3.52.00.00.03.04.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 3.00Buy$16.001,816.17% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50275.72% UpsideTARAProtara Therapeutics 3.14Buy$20.50559.16% UpsideTNYATenaya Therapeutics 3.00Buy$6.25826.47% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, TARA, TNYA, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.005/9/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ATNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-1,132.38%-273.91%9/26/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ATARAProtara Therapeutics-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%N/ATNYATenaya Therapeutics-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)Latest ESLA, TARA, TNYA, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TNYATenaya Therapeutics-$0.17N/AN/AN/AN/AN/A8/6/2025Q2 2025TNYATenaya Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/A5/7/2025Q1 2025TNYATenaya Therapeutics-$0.18-$0.24-$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.220.22IKTInhibikase TherapeuticsN/A0.850.85TARAProtara TherapeuticsN/A18.0318.03TNYATenaya TherapeuticsN/A6.686.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%IKTInhibikase Therapeutics3.81%TARAProtara Therapeutics38.13%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma55.10%IKTInhibikase Therapeutics7.30%TARAProtara Therapeutics8.40%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableTARAProtara Therapeutics3038.58 million35.34 millionOptionableTNYATenaya Therapeutics110162.67 million83.53 millionOptionableESLA, TARA, TNYA, and IKT HeadlinesRecent News About These CompaniesTenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday4 hours ago | marketbeat.comTenaya (TNYA) Q2 Loss Narrows 59%5 hours ago | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6 at 4:30 PM | globenewswire.comQ2 EPS Forecast for Tenaya Therapeutics Lowered by AnalystAugust 5 at 2:15 AM | americanbankingnews.comEquities Analysts Offer Predictions for TNYA Q1 EarningsAugust 4 at 2:32 AM | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Consensus Target Price from BrokeragesAugust 4 at 2:59 AM | americanbankingnews.comLifesci Capital Issues Negative Outlook for TNYA EarningsAugust 4 at 2:12 AM | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from AnalystsAugust 1, 2025 | marketbeat.comTenaya Therapeutics stock rises after positive safety reviews for heart gene therapiesJuly 30, 2025 | investing.comTenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedJuly 30, 2025 | globenewswire.comTNYA - Tenaya Therapeutics Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMTNYA - Tenaya Therapeutics Inc Trailing Returns - MorningstarJuly 8, 2025 | morningstar.comMTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Rating of "Buy" from AnalystsJuly 7, 2025 | marketbeat.comTenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deTenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 15, 2025 | globenewswire.comWhy Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%May 15, 2025 | aaii.comATenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual MeetingMay 15, 2025 | nasdaq.comTenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)May 11, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla: 2 Plays Ahead of Next Week's Earnings ReportBy Sam Quirke | July 15, 2025View Tesla: 2 Plays Ahead of Next Week's Earnings ReportThis Fund Manager Says You Should Get Out of Tesla and Apple—NowBy Brian O'Connell | July 16, 2025View This Fund Manager Says You Should Get Out of Tesla and Apple—NowTSLA Earnings Week: Can Tesla Break Through $350?By Sam Quirke | July 21, 2025View TSLA Earnings Week: Can Tesla Break Through $350?Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control?By Sam Quirke | July 24, 2025View Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control?3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyBy Sam Quirke | July 28, 2025View 3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyESLA, TARA, TNYA, and IKT Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$0.84 -0.02 (-1.76%) Closing price 08/6/2025 03:58 PM EasternExtended Trading$0.86 +0.03 (+3.11%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Inhibikase Therapeutics NYSE:IKT$1.73 -0.07 (-3.89%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$1.65 -0.08 (-4.62%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Protara Therapeutics NASDAQ:TARA$3.11 -0.04 (-1.27%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$6.10 +2.99 (+96.14%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Tenaya Therapeutics NASDAQ:TNYA$0.67 -0.02 (-2.99%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$0.71 +0.03 (+4.95%) As of 06:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
